US Pharma MarketingHow MRD Testing Is Reshaping Breast Cancer Risk Assessment
New B-59 data shows circulating tumor DNA (ctDNA) and molecular residual disease (MRD) testing can better predict recurrence risk and help guide more personalized care in TNBC.
New B-59 data shows circulating tumor DNA (ctDNA) and molecular residual disease (MRD) testing can better predict recurrence risk and help guide more personalized care in TNBC.
Source: Fierce Healthcare